(Bloomberg) -- Oil extended gains in Asia on expectations U.S. President-elect Joe Biden’s incoming administration will take steps to revive growth and energy demand in the world’s largest economy.Futures in New York edged above $53 a barrel after closing up 1.2% on Tuesday. Treasury Secretary nominee Janet Yellen called on lawmakers to “act big” on stimulus, which could provide a boost to consumption while coronavirus vaccines continue to be rolled out. A weaker U.S. dollar is also increasing the appeal for commodities like oil that are priced in the currency.The optimism was tempered somewhat as the International Energy Agency cut forecasts for global oil demand as renewed lockdowns to contain the pandemic weigh on consumption. The Paris-based agency lowered its demand estimate for this quarter by 600,000 barrels a day in its monthly report.The IEA’s gloomier outlook is a validation of Saudi Arabia’s decision earlier this month to unilaterally cut production in February and March. That’s helped oil to keep rallying this year, along with a weak dollar and fund flows into commodities as a hedge against a likely acceleration in inflation this year.“Investors are pricing in a very chunky stimulus” in the U.S. that should weaken the dollar, which would be good for oil, said Stephen Innes, chief global market strategist at Axi. “OPEC+’s current supply discipline coalescing with the Biden administration’s overarching focus on public health and economic response to the Covid-19 pandemic suggests oil prices can go much higher.”The near-term trajectory of oil’s demand recovery has lost some momentum, however. The Chinese government is calling for citizens not to travel over the Lunar New Year holidays, while much of Japan is under a state of emergency and several European nations are still locked down.For 2021 as a whole, the IEA trimmed its demand forecast by 300,000 barrels a day. Global fuel consumption will increase by 5.5 million barrels a day this year, following an unprecedented collapse of 8.8 million a day in 2020, it said.The oil future curve is reflecting expectations for supplies to tighten. Brent’s prompt timespread is 6 cents a barrel in backwardation, a bullish structure where near-dated prices are more expensive than later-dated ones. It was 7 cents in contango in early January.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) today announced that its board of directors has appointed Sameer S. Bharadwaj as its new Chief Executive Officer, effective February 1st, 2021. Mr. Bharadwaj will succeed Daniel Martínez-Valle, who has resigned from the position by mutual agreement with the board. Mr. Martínez-Valle will remain in his current position to support Mr. Bharadwaj through the end of January to ensure an orderly and effective leadership transition.
Joe Biden puts family before anything else.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Penumbra, Inc. (NYSE: PEN) investors to submit their losses now. A securities fraud class action has been filed, and certain investors may have valuable claims. Class Period: Aug. 3, 2020 – Dec. 15, 2020Lead Plaintiff Deadline: Mar. 16, 2021Visit: www.hbsslaw.com/investor-fraud/PENContact An Attorney Now: PEN@hbsslaw.com 844-916-0895 Penumbra, Inc. (PEN) Securities Class Action: The complaint alleges that Penumbra misled investors about the company’s Jet 7 Xtra Flex, a flagship product for treating strokes. According to the complaint, Defendants repeatedly assured investors that the Jet 7 Xtra Flex was “absolutely safe,” “exactly what we hoped it would be,” and “not a product that has any possibility of needing to be recalled.” In truth, Defendants allegedly knew that (1) the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; and (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues. The truth emerged through a series of disclosures ending on Dec. 15, 2020, when Penumbra announced it was voluntarily recalling all configurations of its JET 7 Xtra Flex device because it may be susceptible to damage during use and subsequent patient injury or death. These events have driven the price of Penumbra shares sharply lower. “We’re focused on investor losses and proving Penumbra misled investors about the Jet 7 device’s safety,” said Reed Kathrein, the Hagens Berman partner leading the investigation. If you are a Penumbra investor or have information that may assist our investigation, click here to discuss your legal rights with Hagens Berman. Whistleblowers: Persons with non-public information regarding Penumbra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email PEN@hbsslaw.com. About Hagens BermanHagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw. Contact:Reed Kathrein, 844-916-0895
And the majority of the roles can be done remotely.
Here's how the $100 voucher scheme will be rolled out across NSW.
Trent Baalke took over as the team's interim general manager after Dave Caldwell was fired in November.
(Bloomberg) -- Suspected Russian hackers targeted the cybersecurity company Malwarebytes Inc. in the course of a sprawling cyber-attack that breached U.S. government agencies and companies.The attacker abused “applications with privileged access to Microsoft Office 365 and Azure environments,” according to a Tuesday blog post by Chief Executive Officer Marcin Kleczynski. He said the attack was part of the same hacking campaign that has utilized infected software from SolarWinds Corp. to target other organizations.“After an extensive investigation, we determined the attacker only gained access to a limited subset of internal company emails. We found no evidence of unauthorized access or compromise in any of our internal on-premises and production environments,” Kleczynski wrote.U.S. intelligence agencies and the FBI have said the recent hacking campaign -- which was found and disclosed by the cybersecurity firm FireEye Inc. in December -- was likely undertaken by Russia. In many instances, attackers broke into systems through a compromised version of widely used software from Texas-based SolarWinds Corp.However, analysts have said that SolarWinds’s software wasn’t the only method the suspected Russian hackers used to breach networks. On Tuesday, the firm Symantec discovered a new form of malware used in the attack that wasn’t delivered through SolarWinds, suggesting the hack could be broader than previously understood. The firm CrowdStrike Inc. said the hackers had attempted to break into their networks by compromising a third-party vendor that resells Microsoft services. If a reseller is breached and has access to a client’s credentials, the attacker could then hack into the client’s networks.On Dec. 15, Microsoft alerted Malwarebytes about “suspicious activity from a third-party application” that was consistent with the behaviors of the hackers that had exploited SolarWinds. Upon investigation, Malwarebytes found “no evidence of unauthorized access or compromise in any of our internal on-premises and production environments,” he wrote.Jeff Jones, a Microsoft representative, said in a statement, “Our ongoing investigation of recent attacks has found this advanced and sophisticated threat actor had several techniques in their toolkit. We have not identified any vulnerabilities in our products or cloud services.”Malwarebytes’s disclosure is the latest example of the attackers targeting security companies in the course of the hacking campaign. They stole tools from FireEye and attempted to breach CrowdStrike, the companies said last month.“These attackers were clearly sophisticated and primarily targeted federal agencies and security companies, as far as I’m aware,” Kleczynski said in an email to Bloomberg News.FireEye’s investigation into its own breach last month revealed that the hackers had installed malicious code into SolarWinds’s Orion software, which is used by government agencies and Fortune 500 companies. The malicious code, which customers received by updating the software, provided a launching pad of sorts for further attacks by the hackers into computer networks.According to SolarWinds, as many as 18,000 of its customers may have received infected updates, though the hackers are believed to have conducted further intrusions in far fewer of them. Malwarebytes isn’t a SolarWinds customer.(Updates with Microsoft statement in seventh paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe Laipac Technology Inc. LooK SPOT COVID-19 Antigen Rapid Test of 5 to 8 minutes receives CE IVD Clearance for Europe Richmond Hill, Canada, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Laipac Technology Inc. ("Laipac"), a leader in the development of IoMT (Internet of Medical Things), today announced that their LooK SPOT COVID-19 Antigen Rapid Test received CE IVD clearance for Europe. The LooK SPOT COVID-19 Antigen Rapid Test is a smartphone-based diagnostic device with lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein from SARS-CoV-2 in nasal swabs from patients suspected of COVID-19 within the first eight (8) days of symptom onset. LooK SPOT COVID-19 Antigen Rapid Test uses the nasal sample collected from 1 inch in the nostril. It uses AI technology to deliver real-time test results within 5 to 8 minutes with 97.4% sensitivity and 98.3% specificity in detecting the SARS-CoV-2 virus. LooK SPOT COVID-19 Antigen Rapid Test can also detect the new variant of the SARS-CoV-2 virus first identified in the UK and South Africa. "LooK SPOT's AI algorithm has high accuracy and can identify the color signal in low positive cases when human eyes cannot identify. Healthcare responders in Point of Care often need to make time-sensitive decisions to determine the antigen test results when many patients are within their vicinity. But the tempo, volume, stress, fatigue, lighting, fear, and various other factors can overwhelm healthcare responders when making the visual interpretation of antigen test results. LooK SPOT reduces healthcare responders' cognitive load by providing accurate test results in an easy-to-read format. LooK SPOT has been designed with a tactical edge to fight COVID-19." said Diego Lai. Co-Founder and CEO of Laipac. Patients can download the LooK PASS App from Apple or Google stores to scan the LooK COVID-19 antigen cassette before the test and receive the test results on their phones within 5 to 8 minutes. Negative test results generate a QR code on the app used as a Day Pass to enter the facility or transportation. Laipac also provides API for integration with health & travel applications to control the widespread of the SARS-CoV-2 virus. About Laipac Technology Inc. Laipac Technology Inc. is a leading Canadian company in developing the Internet of Medical Things and Telehealth to improve the overall quality of life and save one person at a time. Founded in 1999 by two Canadian entrepreneurs, Maria C. Pacini and Diego Lai, Laipac Technology Inc. currently exports products and solutions worldwide. For more information, visit: www.laipac.com Media Contact Company Name: Laipac Technology Inc. Contact Person: Diego Lai Email: email@example.com Address: 20 Mural St. Unit 5 City: Richmond Hill State: ON Country: Canada Website: www.laipac.com This news has been published for the above source. Laipac Technology Inc. [ID=16496] Disclaimer: The information does not constitute advice or an offer to buy. Any purchase made from this story is made at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling. The content publisher and its distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about. Attachment Laipac Technology Inc.
CTV journalist Krista Sharpe has posted a clip calling out the person who harassed her while she was trying to deliver a report. Source: Twitter/@KristajSharpe
Matildas coach Tony Gustavsson is keen to prepare his side for the do-or-die nature of big tournaments by playing the best teams as soon and often as possible.
Matildas boss Tony Gustavsson wants to bring a fresh pair of eyes to Australia's talent pool before making any decisions on how to build the squad.
Adalimumab Biosimilar Report covers the updated marketed and pipeline drug profiles, including clinical and non-clinical stage products, and highlights the inactive pipeline products. It also includes the therapeutics assessment by product type, stage, route of administration, and molecule type.Los Angeles, USA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight Adalimumab Biosimilar Report covers the updated marketed and pipeline drug profiles, including clinical and non-clinical stage products, and highlights the inactive pipeline products. It also includes the therapeutics assessment by product type, stage, route of administration, and molecule type. Adalimumab Biosimilar Report Highlights Adalimumab Biosimilar Insight, 2021 report provides comprehensive insights about 35+ Key Players and 45+ Marketed and Pipeline Drugs in Adalimumab Biosimilars landscape. In July 2020, the FDA authorised an Adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVie’s reference product Humira, which has been approved and the 28th biosimilar authorised by the FDA.In March 2020, Alvotech informed that it entered into an exclusive license association with DKSH, a market expansion services provider, to commercialise AVT02, a biosimilar to AbbVie’s HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets. In November 2019, Pfizer stated that the FDA had approved Abrilada (adalimumab-afzb) as a biosimilar to Humira (adalimumab), to treat specific patients with Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, adult Crohn's disease, Ulcerative Colitis and Plaque Psoriasis. Pfizer is working on making Abrilada available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. It is slated to launch in 2023.In February 2019, AbbVie announced that they had received approval for an additional indication of HUMIRA, a fully human anti-TNF-α monoclonal antibody, for hidradenitis suppurativa treatment. With this approval, HUMIRA has become the first treatment in Japan and is now approved for 11 indications in Japan.In October 2018, Orion Corporation and Amgen signed a deal for the marketing and sales of AMGEVITA, Finland's first adalimumab biosimilar. Based on its sales value, the original adalimumab product is the most-sold medicine worldwide and in Finland, and its impact on medicine reimbursement costs is significant. In March 2017, AbbVie announced that the U.S. FDA approved the inclusion of moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis in the United States. Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody indicated for alleviating signs and symptoms and prohibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). DelveInsight’s Adalimumab Biosimilar Insight report provides an analysis of several drugs in different clinical development stages, covering marketed, phase III, II, I, and preclinical. It also helps to comprehend clinical trial details, expressive pharmacological action, agreements, and collaborations. Download Free Sample Report, Request @ Adalimumab Biosimilar Pipeline Analysis Adalimumab Biosimilars Marketed Drugs Abrilada by Pfizer Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is administered as a sterile, preservative-free solution for subcutaneous administration. Though sanctioned, it is not yet marketed in the US like various other manufacturers of authorized biosimilar versions of adalimumab, Pfizer has signed a licensing contract with AbbVie; under the deal, Samsung might launch the drug in November 2023. Halimatoz by Sandoz Halimatoz is mostly used in adults when their conditions are severe, moderately severe or exacerbated, or when patients cannot use other treatments. Halimatoz comprises the active substance adalimumab and is a biosimilar medicine. The active substance in Halimatoz, adalimumab, is a monoclonal antibody that has been designed to identify and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is presented at high levels in patients with the diseases that Halimatoz is used for treatment. By attaching to TNF, adalimumab inhibits its activity, thereby lessening inflammation and other symptoms of the diseases. For further product profiles, access @ Adalimumab Biosimilars Marketed Drugs Adalimumab Biosimilars Emerging Drugs IBI303 by Innovent Biologics IBI303 is a recombinant human monoclonal antibody of TNF-α that has the same amino acid sequence as branded adalimumab (Humira) and displays high degrees of similarity with respect to chemical properties, in vitro biological activity (binding affinity and neutralizing activity against TNF-α), potency, and PK/PD. Pharmacologic and toxicologic studies of IBI303 also stated high similarity to Humira. Clinical studies have displayed that IBI303 can substantially lessen the Ankylosing Spondylitis symptoms and physical signs and reduce the disease activity and enthesitis while improving both somatic motor ability and mobility of the spine in Ankylosing Spondylitis patients. IBI303 may meet Chinese patients' urgent needs with an affordable price at global quality standards. CT-P17 by Celltrion CT-P17 is the first high-concentration type of medicine for a biosimilar made of adalimumab. The company has differentiated CT-P17 from presently Humira biosimilars by halving the dosage. By taking the recent trend into account, Celltrion has also eliminated citrate, which can cause pain in self-injection, from its latest product. If Celltrion launches CT-P17, it will finish a robust portfolio of CT-P17 in the global autoimmune disorder treatment market. AVT02 by Alvotech AVT02 is a monoclonal antibody (mAb) and a proposed biosimilar to Humira (adalimumab). It is being developed for the treatment of Plaque Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis. AVT02 acts as immunosuppressants and tumour necrosis factor-alpha inhibitors. For further product drugs, contact @ Adalimumab Biosimilars Emerging Drugs Scope of Adalimumab Biosimilars Report: Coverage: Global Major Players: 35+ Key Companies Prominent Players: Zydus Cadila, Tanvex Biopharma, Synermore Biologics, Shanghai Henlius Biotech, Sandoz, Samsung Bioepis, Prestige BioPharma, PlantPraxis, Pfizer, Outlook Therapeutics, Mylan, Fujifilm Kyowa Kirin Biologics, Mycenax Biotech, Momenta Pharmaceuticals, Meiji Seika Pharma, LG Chem, ISU Abxis, Innovent Biologics, Hisun Pharmaceuticals, Hetero Group, Harvest Moon Pharmaceuticals, Gene Techno Science, Fresenius Kabi, Epirus Biopharmaceuticals, Daiichi Sankyo, Coherus BioSciences, CinnaGen, Celltrion, Boehringer Ingelheim, BioXpress Therapeutics, Bio-Thera Solutions, Bionovis, The Instituto Vital Brazil, Biogen, Biocon, BIOCND, Genor Biopharma, Biocad, Amgen, Alvotech, mAbxience, and many others. Key Drugs Profiles: 45+ Products Adalimumab Biosimilars Drugs: Adaly, TX17, SYN-060, HLX 03, Halimatoz, Hyrimoz, Hadlima, PBP 1502, Abrilada/Amsparity, Abrilada, ONS-3010, MYL-1401A, Hulio, M 923, DMB-3113, LBAL, ISU202, IBI-303, HS 016, Pamera, Idacio/Kromeya, BOW 050, CHS-1420, Cinnora, CT-P17, Cyltezo, BX 2922, BAT-1406/Qleti, QLETLI, Imraldi, MYL 1401A, GB 232, BCD-057, BCD-058, Amgevita, Amjevita, Solymbic, AVT-02, HLX03, SB5/HADLIMA, AMAB, BCD 057, GBS 005, and many others. Phases: Adalimumab Therapies Late-stage (BLA Filed and Phase III) Adalimumab Therapies (Phase II)Adalimumab Therapies (Phase I) Adalimumab Therapies Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Molecule Types: Small moleculeMonoclonal antibodiesPeptideProtein Route of Administration: Subcutaneous Product Types: MonoCombination Mono/Combination Which are the Key Questions regarding Current Adalimumab Drug Treatment Landscape and Emerging Therapies Answered in the Pipeline Report? What are the current options for Adalimumab treatment?How many companies are developing therapies for the treatment of Adalimumab? How many Adalimumab emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Adalimumab?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Adalimumab market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Adalimumab? What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Adalimumab therapies? What are the key designations that have been granted for the emerging therapies for Adalimumab? How many patents are granted and pending for the emerging therapies for the treatment of Adalimumab? Table of Contents 1Key Insights2Adalimumab Biosimilars: Snapshot3Adalimumab Biosimilars Executive Summary4Regulatory Outlook For Biosimilars4.1.North America4.2.Europe 4.3. Asia Pacific 4.4.Rest Of The World5Adalimumab (Humira) 6Research and Development7Remicade Biosimilar Emerging Opportunities 8Adalimumab Biosimilars Assessment 9Adalimumab Biosimilars Profiles: By Company 9.1.Abrilada: Pfizer 9.2.Hulio: Fujifilm Kyowa Kirin Biologics9.3. HLX 03: Shanghai Henlius Biotech 9.4.Pamera: Hetero Biopharma 9.5.Qletli: Bio-Thera Solutions 10Adalimumab Biosimilars Comparative Landscape: By Company 11Adalimumab Biosimilars Competitive Landscape 12Adalimumab Biosimilars Market Drivers13Adalimumab Biosimilars Market Drivers14Adalimumab Biosimilars SWOT Analysis15Appendix16Bibliography17DelveInsight Capabilities18Disclaimer19About DelveInsight Browse Detailed TOC, Emerging Drugs and Key Companies @ Adalimumab Biosimilars Competitive Landscape Related Reports Insulin Glargine Biosimilar “Insulin Glargine Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars. Rheumatoid Arthritis Market Analysis DelveInsight's Rheumatoid Arthritis (RA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of the disease in 7MM. Psoriatic Arthritis Market Analysis DelveInsight's Psoriatic Arthritis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Juvenile Idiopathic Arthritis Market Analysis DelveInsight's Juvenile Idiopathic Arthritis (JIA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Ankylosing Spondylitis Market Analysis DelveInsight's Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical forecasted epidemiology. Psoriasis Vulgaris Market Analysis DelveInsight's Psoriasis Vulgaris - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology. Crohn's Disease Market DelveInsight's Crohn's Disease (CD) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. Hidradenitis Suppurativa Market Analysis Hidradenitis Suppurativa Market Research Report present a detailed analysis of the market listing HS Epidemiology, Drug therapies and pipeline for study period from 2017-2030. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
China's $16 trillion sovereign debt market is the proverbial elephant in the investment room. It's looking increasingly alluring for European pension funds swimming in sub-zero bond yields as aging populations stretch their finances. For some, the benefits are beginning to outweigh the political risks, and they are upping allocations to China, or considering doing so, according to Reuters' interviews with half a dozen firms that advise and manage money for pension funds.
Surging demand for consumer electronics, rising demand for advanced technologies, and the growing adoption of energy-efficient solutions are key parameters fueling the thermal interface materials market growth.Vancouver, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Global Thermal Interface Materials Market is foreseen to be valued at nearly USD 2.67 Billion by 2027, registering a robust 11.4% CAGR over the forecast timeline. The global thermal interface materials market is projected to record substantially high growth over the forecast period, primarily owing to factors like the increasing demand for thermal management for the smooth operation of electronic devices, surging implementation of these materials in the manufacture of different computer hardware components, consumer electronic products, telecommunications infrastructure, and various automotive components. The global market growth can be further attributed to the consistently rising demand for improved networking solutions, advanced computing technologies, state-of-the-art electronic devices, energy-efficient lighting solutions like LED lamps, and electrification of various transportation modes. Thermal interface materials are generally inserted between two hard surfaces to conduct heat efficiently. These materials offer heat management solutions for modern electronic devices and improve their overall performance and durability. The materials are extensively used for their robust mechanical properties, such as thermal resistance, electrical insulation, material compatibility, and enhanced performance. The most common examples include thermal tapes, greases, solders, and elastomeric pads. Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3340 Widespread commercial availability of thermal interface materials, coupled with their increasing applications in the electronics industry, is expected to bolster the growth of this market in the future. Suring penetration of mobile devices like smartphones and tablets, the emergence of Artificial Intelligence (AI) and the Internet of Things (IoT), mounting adoption of electric and hybrid vehicles, and growing focus on reducing energy consumption and greenhouse gas emissions are the other indispensable factors contributing to the global market growth. The emerging trend of automation has encouraged numerous companies worldwide to gradually integrate advanced automation technologies into certain electronic equipment. Moreover, demand for thermal interface materials in forms of dispensable gels, insulating pads, gap fillings, adhesive tapes, and greases has augmented significantly due to their high chemical resistance, toughness, tensile strength, and excellent thermal conductivity, which, in turn, has boosted the market growth. Key findings of the report: The IT & telecom industry has emerged as the leading market segment among the various end-user industries. The rising use of computers and various other electronic devices in this sector is a key parameter inducing the growth of this segment. The IT segment accounted for a significant market share of 21.78% in 2019 and is likely to flourish at a CAGR of 11.6 % over the forecast period.Among the leading market regions, North America is the largest thermal interface materials market, with the highest revenue share. The region’s booming electronics industry, introduction of technologically advanced electronic devices, growing automotive and IT & telecom sectors, and surging demand for advanced equipment in the healthcare sector are pivotal factors accelerating the global market growth.Major companies operating across the global thermal interface materials market include Bergquist Company, Henkel AG & Co. KGaA, Indium Corporation, Dow Corning, 3M, Parker Chomerics, Honeywell Internatrional Inc., Momentive Performance Materials Inc., Laird Technologies, and Zalman Tech Co., Ltd. Buy Your Copy Now (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3340 For the purpose of this report, the global thermal interface materials market has been segmented, based on product type, application, end-user industry, and region: Product Type Outlook (Revenue, USD Billion; 2017-2027) Greases & AdhesivesTapes & FilmsElastomeric PadsPhase-change MaterialsMetal-based MaterialsOthers Application Outlook (Revenue, USD Billion; 2017-2027) GaN SemiconductorsMobiles & TabletsLaptops & DesktopsData CentersLEDsElectric VehiclesOthers End-User Industry Outlook (Revenue, USD Billion; 2017-2027) IT & TelecomHealthcare Automotive Consumer & Power Electronics ChemicalOthers Click on the link to read key highlights of the report and look at projected trends for years to come: https://www.reportsanddata.com/report-detail/thermal-interface-materials-market Regional Outlook (Revenue, USD Billion; 2017-2027) North America U.S.Canada Europe U.K.FranceGermanyBENELUXRest of Europe Asia Pacific JapanChinaIndia South KoreaRest of Asia Pacific Latin America BrazilRest of Latin America Middle East & Africa Saudi ArabiaU.A.E.Rest of Middle East & Africa Take a Look at our Related Reports: Agricultural Biostimulants Market Analysis By Type (Acid-based, Extract-based, Others), By Application (Soil, Foliar, Seed and Others) And Segment Forecasts, 2017-2026 Potash Fertilizers Market Share, Size & Analysis, By Product Type (Potassium Chloride, Potassium Nitrate, Sulfate of Potash), By Mode of Application (Foliar, Broadcasting, Fertigation), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses), 2017-2027 Seed Treatment Market Size, Share & Demand, By Type (Chemical Seed Treatment, Biological Seed Treatment), By Crop Type, By Application Technique, By Function And By Region, Forecasts To 2027 Biopesticides Market Size, Share & Analysis, By Product Type (Bioherbicides, Bioinsecticides, Bionematicides), By Crop Type, By Mode of Application, By Source, By Formulation, And By Region, Forecasts To 2027 Phosphate Fertilizer Market Demand, Share & Outlook, By Product Type (Superphosphate, Monoammonium Phosphate, Diammonium Phosphate), By Application, By Distribution Channel And By Region, Forecasts To 2027 About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: email@example.com LinkedIn | Twitter | Blogs Read Full Press Release@ https://www.reportsanddata.com/press-release/global-thermal-interface-materials-market
Deion Sanders' truck was broken into early on Monday morning in Mississippi.
Limiting air pollution to levels recommended by the World Health Organization could prevent more than 50,000 deaths in Europe annually, according to research published Wednesday that called for urgent action.
Medical experts do not believe a psychosis that led a NSW man to kill his gran and a retired police officer was drug-induced, prosecutors have accepted.
Just under 20,000 people were tested in NSW in the latest reporting period, almost double the figure for the day before, with no local coronavirus cases found.
* Monday's risk-averse moves unwind as Yellen urges spending * Euro gains on bright German investor sentiment, Italian politics * Graphic: World FX rates https://tmsnrt.rs/2RBWI5E By Tom Westbrook SINGAPORE, Jan 20 (Reuters) - The U.S. dollar nursed losses on Wednesday and the euro hung on to gains as investors' mood brightened in the wake of a better-than-expected sentiment survey in Germany and big spending talk from U.S. Treasury Secretary nominee Janet Yellen. Yellen's comments, urging lawmakers to "act big" on coronavirus relief and not worry too much about debt, helped assuage this week's risk averse tone and knocked the dollar index from a one-month high.